Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

ACEI/ARB therapy benefits for hypertensive patients who have diabetes

May 31, 2013

There are many potential benefits of treating your hypertensive patients who have diabetes with a regimen that includes either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) medication. Because of these benefits, several national and international guidelines recommend the use of ACEI/ARBs as anti-hypertensive agents when patients have a diagnosis of diabetes, unless contraindicated or not clinically tolerated. ACEI/ARB therapy has been shown to decrease the rate of progression of kidney disease in patients who have diabetes, independent of their ability to lower blood pressure. According to the American Diabetes Association?s Standards of Medical Care in Diabetes ? 2013, the use of these drugs in this population reduces cardiovascular morbidity and mortality, and if one class of medication is not tolerated, the other should be substituted. Although the majority of physicians are using ACEI/ARBs in their patients who have hypertension and diabetes, physicians may sometimes choose to discontinue ACEI/ARB therapy when a patient?s renal function begins to decline and serum potassium levels start to rise, precisely the time when these medications may be of the most use. It is important to note that ACEI/ARBs can often be used safely and will improve renal outcomes in stable patients with diabetes, even if they have poor renal function (GFR < 30mL/min). Please consider the potential advantages of ACEI/ARBs for your hypertensive patients who have diabetes. Most ACEI/ARBs are available generically. In mid-June we will be adding a new Clinical Alert to assist you in identifying members who may benefit from ACEI/ARB therapy. For instructions on how to access Clinical Alerts for your patients, please review our Clinical Alerts Overview, which is available in the Administrative Tools & Resources section of IBC NaviNet[]?[] Plan Central. If you have any questions, please contact your Network Coordinator. [

]References[

] [

]Angiotensin Converting Enzyme Inhibitors. J Clin Hypertension. 2011; 13(9): 667.
Efficacy and Safety of Benazepril and Advanced Chronic Renal Insufficiency. N Eng J Med 2006; 354:131.
Executive Summary: Standards of Medical Care in Diabetes ? 2013. Diabetes Care, Volume 36, Supplement 1, January 2013.
Renoprotective Effects of the Angiotensin Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. N Eng J Med 2001; 345(12): 851.[

] [

NaviNet® is a registered trademark of NaviNet, Inc., an independent company.

]

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.